Scholarlink

<p>We compared clinicopathologic features, MammaPrint and BluePrint molecular subtype, and outcomes by race among females with hormone receptor-positive (HR+), HER2- early-stage breast cancer (EBC). Of 1018 participants with HR+ HER2- EBC enrolled from two registries (BEST and FLEX), 509 White females were propensity score matched 1:1 to 509 Black females based on age and/or menopausal status. MammaPrint classified tumors as High-Risk or Low-Risk; and together with BluePrint, classified tumors as Luminal A-Type, Luminal B-Type, or Basal-Type. Recurrence-free survival (RFS) was analyzed by race and molecular subtype. Cox proportional hazards models assessed association of clinicopathologic features with outcomes. Basal-Type tumors were more prevalent among Black vs White participants (11.0% vs 4.8%, <i>p</i> &lt; 0.001). Independent of race, participants with Basal-Type tumors had lower 3-year RFS (83.7%) compared to Luminal B-Type (93.7%) and Luminal A-Type (96.5%, <i>p</i> &lt; 0.0001). Multivariate analysis revealed that participants with High-Risk, Luminal B- and Basal-Type tumors had significantly worse 3-year outcomes compared to Low-Risk Luminal A-Type, after controlling for race and potential confounders. Genomic classification identified higher proportions of High-Risk HR+ HER2- EBC among Black participants. Molecular subtype was independently prognostic of 3-year survival, supporting the prognostic and potentially predictive importance of genomic testing to reduce racial survival disparities among Black females with EBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Sonya Reid,
  • Lindsay Venton,
  • Jennifer G. Whisenant,
  • Anne E. Weidner,
  • Jennifer Wei,
  • Harshini Ramaswamy,
  • Christa Dreezen,
  • Nicole Chmielewski-Stivers,
  • Andrea R. Menicucci,
  • William Audeh,
  • Tuya Pal

摘要

We compared clinicopathologic features, MammaPrint and BluePrint molecular subtype, and outcomes by race among females with hormone receptor-positive (HR+), HER2- early-stage breast cancer (EBC). Of 1018 participants with HR+ HER2- EBC enrolled from two registries (BEST and FLEX), 509 White females were propensity score matched 1:1 to 509 Black females based on age and/or menopausal status. MammaPrint classified tumors as High-Risk or Low-Risk; and together with BluePrint, classified tumors as Luminal A-Type, Luminal B-Type, or Basal-Type. Recurrence-free survival (RFS) was analyzed by race and molecular subtype. Cox proportional hazards models assessed association of clinicopathologic features with outcomes. Basal-Type tumors were more prevalent among Black vs White participants (11.0% vs 4.8%, p < 0.001). Independent of race, participants with Basal-Type tumors had lower 3-year RFS (83.7%) compared to Luminal B-Type (93.7%) and Luminal A-Type (96.5%, p < 0.0001). Multivariate analysis revealed that participants with High-Risk, Luminal B- and Basal-Type tumors had significantly worse 3-year outcomes compared to Low-Risk Luminal A-Type, after controlling for race and potential confounders. Genomic classification identified higher proportions of High-Risk HR+ HER2- EBC among Black participants. Molecular subtype was independently prognostic of 3-year survival, supporting the prognostic and potentially predictive importance of genomic testing to reduce racial survival disparities among Black females with EBC.